180 Life Sciences Granted Extension By Nasdaq Hearing Panel To Regain Compliance With Continued Listing Requirements
Portfolio Pulse from Benzinga Newsdesk
180 Life Sciences has been granted an extension by the Nasdaq Hearing Panel to regain compliance with continued listing requirements, according to an SEC filing.
July 02, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
180 Life Sciences has received an extension from the Nasdaq Hearing Panel to meet continued listing requirements, as per an SEC filing.
The extension granted by the Nasdaq Hearing Panel provides 180 Life Sciences with additional time to meet the necessary requirements for continued listing. This is a positive development as it reduces the immediate risk of delisting, which could have negatively impacted the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100